Larysa Sanchez, MD from Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute speaks about the ASH 2020 Abstract…
Browsing: Multiple Myeloma
Robert M. Rifkin, MD of the Rocky Mountain Cancer Center speaks about the ASH 2020 Abstract – 3247 DREAMM-7: A…
Robert M. Rifkin, MD of the Rocky Mountain Cancer Center speaks about the ASH 2020 Abstract – 551 The Phase…
Maximilian Merz, MD from Roswell Park Comprehensive Cancer Center speaks about 722 Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma.Introducing:In…
Phillipe Moreau, MD from the University Hospital of Nantes discusses the ASH 2020 abstract – 2316 Isatuximab Plus Carfilzomib and…
Amrita Krishnan, MD, FACP of the City of Hope speaks about the ASH 2020 abstract – 180 Updated Phase 1…
Fredrik Schjesvold, MD, Ph.D. from Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University…
Peter Voorhees, MD – Director of Outreach for Hematologic Malignancies at Atrium Health’s Levine Cancer Institute speaks about ASH 2020…
Jason Valent, MD of the Cleveland Clinic speaks about the ASH 2020 abstract – 729 Safety, Tolerability and Efficacy of…
Thierry Facon, MD from the Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille discusses the…
Raymond Comenzo, MD – Director, Transfusion Services, Tufts Medical Center; Director, John C. Davis Myeloma and Amyloid Program, Tufts Medical…
Deepu Madduri, MD – Assistant Professor, Hematology and Medical Oncology of the Mount Sinai Hospital, Mount Sinai Beth Israel discusses…
Alfred L. Garfall, MD, MS – Assistant Professor of Medicine, Perelman School of Medicine discusses ASH 2020 abstract – 180…
Sara Bringhen, MD University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino speaks about ASH 2020…
Meletios A. Dimopoulos, MD – Professor, and Chairman of the Department of Clinical Therapeutics National and Kapodistrian University of Athens…
Ajai Chari, MD, Ph.D. – Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the…
Smith Giri, MD, MHS Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology The University of Alabama at…
Kirollos S. Hanna, PharmD, BCPS, BCOP, Oncology Pharmacy Manager, M Health Fairview – Maple Grove; Assistant Professor of Pharmacy, Mayo…
Saad Usmani, M.D., MBA, FACP, Department of Hematologic Oncology and Blood Disorders of Atrium Health Levine Cancer Institute discusses Daratumumabâ€lenalidomideâ€dexamethasone…
Amrita Krishnan, MD, FACP of City of Hope S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct…
Andrzej Jakubowiak, MD, Ph.D. of the University of Chicago Comprehensive Cancer Center speaks on the ASCO 2020 abstract Orvacabtagene autoleucel…
Paul G. Richardson, MD of Dana-Farber Cancer Institute explains the abstract entitled First-in-human phase I study of the novel CELMoD…
Nikhil C. Munshi, MD of Dana-Farber Cancer Institute discusses ASCO20 Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in…
Kristen Hege, MD – Bristol Myers Squibb discusses Phase 1 proof-of-concept data (via an oral presentation) on novel CELMoD CC-92480…
Kristen Hege, MD – Bristol Myers Squibb discusses Phase 1 proof-of-concept data (via an oral presentation) on novel CELMoD CC-92480…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene…
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in…
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in…
Nikhil C. Munshi, M.D of Dana Farber Cancer Institute discusses the positive results from pivotal KarMMa study of Ide-cel in…
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib…
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib…
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous…
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous…
Sagar Lonial, MD @SagarLonialMD of Winship Cancer Institute @WinshipAtEmory discusses ixazomib vs placebo maintenance for NDMM patients not undergoing autologous…
Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple…
Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple…
Mike Thompson, MD, PhD @mtmdphd of Aurora Cancer Care @Aurora_Cancer discusses global rates of influenza and pneumococcal vaccination in multiple…
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor…
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor…
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the phase I study of teclistamab, a humanized B-cell…
Saad Z. Usmani, M.D @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj),…
Saad Z. Usmani, M.DÂ @szusmani of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a…
Saad Z. Usmani, M.D of Levine Cancer Institute @LevineCancer discusses the FDA approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a…
Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly…